SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
NEW YORK, Aug. 16, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intellipharmaceutics International Inc. ("Intellipharmaceutics") (NASDAQ:IPCI) securities between January 14, 2016 and July 26, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sbm/intellipharmaceutics-international-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Intellipharmaceutics failed to conduct a human abuse liability study to support its Rexista New Drug Application (“NDA”); (2) the Company did not include abuse-deterrent studies conducted to support abuse-deterrent label claims related to abuse of the drug by various pathways; (3) the Company was not submitting sufficient data to support approval of the NDA; and (4) as a result, Defendants’ statements about Intellipharmaceutics’ business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Intellipharmaceutics you have until September 29, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/intellipharmaceutics-international-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
